PDF DatasheetHuman Anti-Cdc20 Antibody Product Attributes
Cdc20 Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-CDC20 antibody staining is expected to be primarily localized to the cytosol and nucleoplasm. There is variability in either the signal strength or the localization of signal in cytosol and nucleoplasm from cell to cell.
Observed Antibody Staining Data By Tissue Type:
Variations in Cdc20 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in glandular cells in the appendix, small intestine, stomach. More moderate antibody staining intensity was present in glandular cells in the appendix, small intestine, stomach. Low, but measureable presence of Cdc20 could be seen in cells in the tubules in kidney, glandular cells in the breast and salivary gland, non-germinal center cells in the lymph node, respiratory epithelial cells in the nasopharynx and urothelial cells in the urinary bladder. We were unable to detect Cdc20 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of Cdc20 expression as measured by anti-Cdc20 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | ++ | – | +++ | ++ | ++ | ++ | + | + | ++ | ++ | ++ | ++ | + | ++ | + | ++ | + | ++ | + | ++ |
| CDC20 Variability | + | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | +++ | ++ | ++ | + | +++ | ++ | ++ | ++ |
| Cdc20 General Information | |
|---|---|
| Alternate Names | |
| Cell-Division Cycle Protein 20, CDC20 | |
| Molecular Weight | |
| 55kDa | |
| Chromosomal Location | |
| 1p34.2 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | CDC20 |
| Entrez Gene ID | 991 |
| Ensemble Gene ID | ENSG00000117399 |
| RefSeq Protein Accession(s) | NP_001246 |
| RefSeq mRNA Accession(s) | NM_001255 |
| RefSeq Genomic Accession(s) | NC_000001, NC_018912 |
| UniProt ID(s) | Q12834 |
| UniGene ID(s) | Q12834 |
| HGNC ID(s) | 1723 |
| Cosmic ID(s) | CDC20 |
| KEGG Gene ID(s) | hsa:991 |
| PharmGKB ID(s) | PA26257 |
| General Description of Cdc20. | |
| Cyclins, regulatory subunits, which associate with kinases, control many of the important steps in cell cycle progression. The Cdc2 protein kinase (p34Cdc2) exhibits protein kinase activity in vitro, exists in a complex with both cyclin B, a protein homologous to p13SUC1. Cdc2 kinase is the active subunit of the M phase promoting factor (MPF), the M phase-specific Histone H1 kinase. The p34Cdc2/cyclin B complex is required for the G2 to M transition. An additional cell cycle-dependent protein kinase, termed p55cdc, exhibits a high degree of homology with the S. cerevisiae proteins Cdc20, Cdc4. The p55cdc transcript is readily detectable in a variety of cultured cell lines in growth phase, but disappears when cell growth is chemically arrested. | |
There are no reviews yet.